Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market

Impact · against what's priced in

Rhythm Pharmaceuticals sees a potential valuation catalyst through the expansion of Imcivree into the hypothalamic obesity market, with projected revenues exceeding $2 billion by 2030. While a Phase 3 trial success has already driven a stock rally, the specific analyst-driven revenue targets and the March 20 FDA decision date provide concrete near-term anchors for the price.

RYTM+0.50

No priced-in read yet